Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Oncogene

Volumn 26, Issue 49, 2007, Pages 6997-7005

  Bostner, J ^a   Ahnstrom Waltersson M ^a,c   Fornander, T ^b   Skoog, L ^b   Nordenskjold B ^a   Stal O ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Cyclin D1; Drug resistance; Pak1; Real time PCR

Indexed keywords

CYCLIN D1; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; P21 ACTIVATED KINASE 1; TAMOXIFEN; TUMOR MARKER;

AMPLICON; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMOSENSITIVITY; CHROMOSOME 11Q; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; POSTMENOPAUSE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLINS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; P21-ACTIVATED KINASES; POSTMENOPAUSE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TAMOXIFEN;

EID: 35549002845     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210506     Document Type: Article

References (43)

1. Ahnström M, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. (2005). Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance. Breast Cancer Res Treat 91: 145-51.
2. Albertson DG. (2006). Gene amplification in cancer. Trends Genet 22: 447-55.
3. Ali S, Coombes RC. (2002). Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2: 101-12.
4. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al. (2004). Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-540.
5. Askmalm MS, Carstensen J, Nordenskjöld B, Olsson B, Rutqvist LE, Skoog L et al. (2004). Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients. Acta Oncol 43: 235-44.
6. Balasenthil S, Barnes CJ, Rayala SK, Kumar R. (2004a). Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 567: 243-47.
7. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK et al. (2004b). p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279: 1422-428.
8. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D et al. (1997). Detailed map of a region commonly amplified at 11q13 → q14 in human breast carcinoma. Cytogenet Cell Genet 79: 125-31.
9. Bernards R. (1999). CDK-independent activities of D type cyclins. Biochim Biophys Acta 1424: M17-22.
10. Bièche I, Olivi M, Nogues C, Vidaud M, Lidereau R. (2002). Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86: 580-86.
11. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA et al. (2006). Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100: 264-70.
12. Champeme MH, Bièche I, Lizard S, Lidereau R. (1995). 11q13 amplification in local recurrence of human primary breast cancer. Genes Chromosomes Cancer 12: 128-33.
13. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H et al. (2000). Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60: 1077-083.
14. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179-86.
15. Fantl V, Richards MA, Smith R, Lammie GA, Johnstone G, Allen D et al. (1990). Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 26: 423-29.
16. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. (2004). Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-447.
17. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR et al. (2003). Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 1: 300-11.
18. Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G. (2006). Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98: 671-80.
19. Jin S, Zhuo Y, Guo W, Field J. (2005). p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 280: 24698-4705.
20. Jirström K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stål O et al. (2005). Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 65: 8009-016.
21. Jordan VC. (2006). Pak up your breast tumor - and grow!. J Natl Cancer Inst 98: 657-59.
22. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E et al. (1994). Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 9: 42-8.
23. Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M et al. (1997). Cyclin-D1-gene amplification is a more potent prognostic factor than its protein overexpression in human head-and-neck squamous-cell carcinoma. Int J Cancer 74: 576-81.
24. Li F, Adam L, Vadlamudi RK, Zhou H, Sen S, Chernoff J et al. (2002). p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep 3: 767-73.
25. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, Lohrs U et al. (2006). Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126: 101-09.
26. Menard RE, Jovanovski AP, Mattingly RR. (2005). Active p21-activated kinase 1 rescues MCF10A breast epithelial cells from undergoing anoikis. Neoplasia 7: 638-45.
27. Miyamoto R, Uzawa N, Nagaoka S, Hirata Y, Amagasa T. (2003). Prognostic significance of cyclin D1 amplification and overexpression in oral squamous cell carcinomas. Oral Oncol 39: 610-18.
28. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J et al. (1997). Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17: 5338-347.
29. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. (2003). Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78: 323-35.
30. Rayala SK, Molli PR, Kumar R. (2006a). Nuclear p21-activated kinase 1 in breast cancer packs off tamoxifen sensitivity. Cancer Res 66: 5985-988.
31. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA et al. (2006b). P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66: 1694-701.
32. Rennstam K, Baldetorp B, Kytola S, Tanner M, Isola J. (2001). Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 61: 1214-219.
33. Rutqvist LE, Johansson H. (2006). Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among 'high risk' pre- and postmenopausal breast cancer patients. Acta Oncol 45: 517-27.
34. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T et al. (2003). Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163: 985-92.
35. Schuuring E. (1995). The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene 159: 83-6.
36. Singh RR, Song C, Yang Z, Kumar R. (2005). Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem 280: 18130-8137.
37. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A et al. (2000). Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275: 36238-6244.
38. Vadlamudi RK, Barnes CJ, Rayala S, Li F, Balasenthil S, Marcus S et al. (2005). p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 25: 3726-736.
39. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. (2002). P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 21: 5437-447.
40. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. (2006). PAK1 hyperactivation is sufficient for mammary gland tumor formation. Oncogene 25: 2931-936.
41. Wong LJ, Dai P, Lu JF, Lou MA, Clarke R, Nazarov V. (2006). AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. BMC Cancer 6: 111.
42. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R. (1998). Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488-498.
43. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. (1997). CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-15.